DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema

NCT06004986 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

216

Enrollment

OTHER

Sponsor class

Conditions

Atopic Dermatitis
Atopic Dermatitis Eczema

Interventions

DRUG: Dupilumab

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Collaborators

[object Object]
[object Object]